Fate Therapeutics Inc
FATE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001434316
In the last 90 days, Fate Therapeutics Inc insiders filed 0 open-market purchases and 2 sales; 156 institutions reported holding it in 13F filings for Q2 2026, worth $193.2M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Fate Therapeutics Inc changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 132 | 139 | +7 |
| Shares | 96.6M | 79.7M | −16.9M (−17.5%) |
| Value | $76.3M | $88.9M | +$12.6M (+16.5%) |
New holders (28)
Institutions that held Fate Therapeutics Inc at the end of Q2 2025 but not at the end of Q1 2025.
Sold out (21)
Institutions that held Fate Therapeutics Inc at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| OrbiMed Advisors LLC | 1,680,580 | $1.33M |
| Integral Health Asset Management, LLC | 700,000 | $553.1K |
| D. E. Shaw & Co., Inc. | 433,192 | $342.3K |
| Sphera Funds Management Ltd. | 397,177 | $313.8K |
| Exchange Traded Concepts, LLC | 131,830 | $104.2K |
| Susquehanna Fundamental Investments, LLC | 118,186 | $93.4K |
| Comerica Bank | 82,024 | $64.8K |
| Callan Family Office, LLC | 82,024 | $64.8K |
| Walleye Capital LLC | 72,286 | $57.1K |
| Caption Management, LLC | 57,000 | $45.0K |
| Corebridge Financial, Inc. | 49,045 | $38.8K |
| Marshall Wace, LLP | 19,155 | $15.1K |
| Wilshire Advisors LLC | 4,083 | $13.2K |
| Stifel Financial Corp | 11,250 | $8.89K |
| Federated Hermes, Inc. | 5,942 | $4.69K |
| Picton Mahoney Asset Management | 5,369 | $4.00K |
| Coldstream Capital Management Inc | 686 | $542 |
| CoreCap Advisors, LLC | 255 | $201 |
| Legacy Wealth Managment, LLC | 115 | $91 |
| Rothschild Investment LLC | 70 | $55 |
| Covestor Ltd | 31 | $0 |